1212C2
A human monoclonal anti-RBD (SARS-CoV-2 Spike) antibody.
General information
1212C2 is a human monoclonal antibody identified in an IgM memory B cell of a COVID-19 convalescent patient. It was shown to bind SARS-CoV-2 Spike RBD and to neutralize the virus in vitro. The antibody's Fc was modified so that its half-life was increased and Fc receptor binding reduced. 1212C2 displayed protective effect in an animal model viral challenge (Piepenbrink et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters
Spike protein Biophysical assay Animal model In vitro Antibody |
in vitro binding assay; in vitro biophysical assay; Vero E6 cells; golden Syrian hamsters; (VSV) SARS-CoV-2 pseudovirus; SARS-CoV-2 | The antibody displayed high affinity to SARS-CoV-2 Spike protein RBD. It neutralized SARS-CoV-2 in Vero E6 cells with NT50s of 10 ng/mL and 22 ng/mL when used in pre- and post-treatment conditions, respectively. The antibody was potent in a SARS-CoV-2 pseudovirus neutralization assay, as well. Prophylactically and therapeutically administered 1212C2 significantly reduced viral burden and lung pathology in hamsters. The antibody showed high efficacy when applied in a nebulized form at the lowest dose tested (0.6 mg/kg). |
Feb/24/2021 |
